Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum

Farca, Anna Maria; Miniscalco, Barbara; Badino, P.; Odore, R.; Monticelli, P; Trisciuoglio, Andrea; Ferroglio, Ezio

doi:10.1007/s00436-011-2792-7

Cited by 17 publications

(11 citation statements)

References 35 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Careful use of this drug should be mandatory, since resistance can be easily induced in in vitro experiments (85). Miltefosine has recently emerged as a potential tool for CVL treatment, and its use has been evaluated in monotherapy and in combination with other drugs (86, 87). There are no nephrotoxic effects reported, and vomiting is the most common side effect in dogs (88).…”

Section: Miltefosinementioning

confidence: 99%

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

et al. 2014

View full text Add to dashboard Cite

Leishmaniasis has several clinical forms: self-healing or chronic cutaneous leishmaniasis or post-kala-azar dermal leishmaniasis; mucosal leishmaniasis; visceral leishmaniasis (VL), which is fatal if left untreated. The epidemiology and clinical features of VL vary greatly due to the interaction of multiple factors including parasite strains, vectors, host genetics, and the environment. Human immunodeficiency virus infection augments the severity of VL increasing the risk of developing active disease by 100–2320 times. An effective vaccine for humans is not yet available. Resistance to chemotherapy is a growing problem in many regions, and the costs associated with drug identification and development, make commercial production for leishmaniasis, unattractive. The toxicity of currently drugs, their long treatment course, and limited efficacy are significant concerns. For cutaneous disease, many studies have shown promising results with immunotherapy/immunochemotherapy, aimed to modulate and activate the immune response to obtain a therapeutic cure. Nowadays, the focus of many groups centers on treating canine VL by using vaccines and immunomodulators with or without chemotherapy. In human disease, the use of cytokines like interferon-γ associated with pentavalent antimonials demonstrated promising results in patients that did not respond to conventional treatment. In mice, immunomodulation based on monoclonal antibodies to remove endogenous immunosuppressive cytokines (interleukin-10) or block their receptors, antigen-pulsed syngeneic dendritic cells, or biological products like Pam3Cys (TLR ligand) has already been shown as a prospective treatment of the disease. This review addresses VL treatment, particularly immunotherapy and/or immunochemotherapy as an alternative to conventional drug treatment in experimental models, canine VL, and human disease.

show abstract

Section: Miltefosinementioning

confidence: 99%

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The combination between miltefosine and allopurinol caused a significant higher percentage of killed parasites than marbofloxacin plus allopurinol. Marbofloxacin was more efficacious when associated with allopurinol than alone after 72 h of incubation (134). Miltefosine was more efficacious than marbofloxacin, but when compared to meglumine antimoniate and sodium stibogluconate, marbofloxacin was more efficacious, with increases in NO and TNF-α observed after marbofloxacin treatment (135).…”

Section: Antibioticsmentioning

confidence: 99%

Leishmaniasis treatment update of possibilities for drug repurposing

Torres-Santos¹

2018

Front Biosci

View full text Add to dashboard Cite

The leishmaniases represent a public health problem in under-developed countries and are considered a neglected disease by the World Health Organization (WHO). They are cuased by parasites with different clinical manifestations. Currently, there is no vaccine, and treatment is in-efficient and is associated with both serious side effects often leading to resistance to the parasites. Thus, it is essential to search for new treatment strategies, such as drug repurposing, i.e., the use of drugs that are already used for other diseases. The discovery of new clinical applications for approved drugs is strategic for lowering the cost of drug discovery since human toxicity assays are already conducted. Here, we review a broad analysis of the different aspects of this approach for anti-leishmanial treatment.

show abstract

“…This can reduce the parasite burden and improve clinical signs, although relapses have been reported when miltefosine has been administered alone, and therefore combination with allopurinol is preferable (27,28,32). Miltefosine has shown greater efficacy than drugs such as marbofloxacin, whether alone or in combination with allopurinol (10). Meglumine antimonate is administered once or twice per day and subcutaneously for 3-4 weeks, whereas miltefosine is given orally once daily for 4 weeks (9,53).…”

Section: Review Articlementioning

confidence: 99%

Aktuelle Kenntnisse zu Therapie und Prävention der kaninen Leishmaniose

Apostolopoulos¹,

Mitropoulou²,

Thom³

et al. 2018

Tierarztl Prax Ausg K

View full text Add to dashboard Cite

ZusammenfassungDie kanine Leishmaniose ist eine Infektionskrankheit, die zunehmend an Bedeutung gewinnt, da auch in Deutschland der Hauptvektor der Leishmaniose vorkommt und Einzelfälle autochthoner Infektionen beschrieben sind. Der Artikel fasst aktuelle Informationen über Therapie und Prävention der Leishmaniose zusammen. Kürzlich wurden bei Hunden, die unter Allopurinoltherapie ein Rezidiv der Erkrankung erlitten, Allopurinol-resistente Leishmania-infantum-Stämme gefunden. Daher werden alternative Langzeittherapien erforderlich. Auch die Ergebnisse aus Langzeitstudien zur Effizienz von Miltefosin im Vergleich zu Megluminantimonat können die Wahl des leishmaniziden Therapeutikums beeinflussen. Eine Vielzahl verschiedener Repellenzien steht zur Übertragungsprophylaxe zur Verfügung. In Europa sind zwei Impfstoffe für Hunde zugelassen, um das Risiko einer aktiven Infektion und den Schweregrad der klinischen Erkrankung zu reduzieren.

show abstract

Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum

Cited by 17 publications

References 35 publications

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

Leishmaniasis treatment update of possibilities for drug repurposing

Aktuelle Kenntnisse zu Therapie und Prävention der kaninen Leishmaniose

Contact Info

Product

Resources

About